Accessibility settings

This paper is in the following e-collection/theme issue:

#xPharmacologyandTherapeutics (13) #xHealthPolicy (5)

Published on in Vol 6 (2025)

Preprints (earlier versions) of this paper are available at https://www.medrxiv.org/content/10.1101/2024.07.29.24311184v1, first published .
Financial analysis report with charts and graphs held by hands in a lab

Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

Authors of this article:

Manthana Laichapis1 Author Orcid Image ;   Rungpetch Sakulbumrungsil1 Author Orcid Image ;   Khunjira Udomaksorn2 Author Orcid Image ;   Nusaraporn Kessomboon3 Author Orcid Image ;   Osot Nerapusee1 Author Orcid Image ;   Charkkrit Hongthong3 Author Orcid Image ;   Sitanun Poonpolsub4 Author Orcid Image
Article Authors Cited by (4) Tweetations Metrics

Journals

  1. Shkarupeta E. Peer Review of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”. JMIRx Med 2025;6:e77627 View
  2. Laichapis M, Sakulbumrungsil R, Udomaksorn K, Kessomboon N, Nerapusee O, Hongthong C, Poonpolsub S. Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”. JMIRx Med 2025;6:e77623 View
  3. Luksameesate P. Peer Review of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”. JMIRx Med 2025;6:e78090 View
  4. Ancuceanu R, Drăgănescu D, Lascu B, Dinu M. A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within the EU Between 2011 and 2020. Journal of Pharmaceutical and BioTech Industry 2026;3(3):15 View